Name: Qing Li

Professional Title：Associate Professor，

Master’s Supervisor

Office: 717, Jingcheng Building, Lanzhou University

E-mail: lqing@lzu.edu.cn

Research Interests: Tumor development and prevention, tuberculosis subunit vaccine development

 

Education/Training: 2013 Gansu Agriculture Univesity Ph.D. in Science

                   2004 Ningxia Medical College M.D. in Science

                   1994 Lanzhou University Graduation in Clinic Medicine

Projects:

1. Key R&D of Gansu Provincial Science, Target and effect of aconite alkaloid combined drug on metabolism and microenvironment in HCC. 2018.9-2021.8

2. Social Development of Lanzhou Civic Science. The mechanism of PAK4 in liver cancer as a target for diagnosis and treatment. 2015.12‐2017.12

3. NNSFC. Molecular of SurA on the Formation and Survival of retained Escherichia Coli. 2017.1‐2019.12

4. International Cooperation of Gansu Provincial Science, Correlation study of thyroxine receptor ?1 gene mutation and breast cancer.  2010.7‐2014.12

5. Major projects of the Ministry of Science and Technology. Preclinical study on subunit vaccine boosting BCG for TB. 2012.1‐2015.12.

6. NNSFC. Inhibition of regulatory T cell improves immunoreactivity of tuberculosis subunit vaccine by IL-28B and CD25 antibodies. 2011.1‐2013.12.

7. National special science and technology for the prevention and treatment of infectious diseases. Research on tuberculosis subunit vaccine. 2008.1‐2011.12.

 

Publications:

1. Qing Li, Xiaoyun Zhang, Na Wei, et al. p21-activated kinase 4 as a switch between caspase-8 apoptosis and NF-κB survival signals in response to TNF-α in hepatocarcinoma cells. BBRC (accepted).

2. Qing Li, Fengge Yang, Wen Li et al. Preparation and application of two aconite alkaloids combined drugs on liver cancer. 2018.1.23, China, 201810044106.X (in Chinese)

3. Yaqin Ling; Xiaoling Ling; Lu Fan; Yong Wang; Qing Li (corresponding author) Mutation analysis underlying the down-regulation of the thyroid hormone receptor β1 gene in the Chinese breast cancer population. Oncotargets and therapy, 16 (8); 2967–2972, 2015.

4. Yaqin Ling; Qing Li (corresponding author); et al. Loss of Heterozygosity in thyroid hormone receptor beta in invasive breast cancer. Tumori, 101(5):572-577, 2015.

5. Baoyuan Liu, Bindong Zhu, Yonghao Hu, Hongxia Niu,Juan Su, Kefeng Tang,Wanbo Liu, Hongfei Kang, Qing Li (corresponding author). The effects of CpG-ODN and PolyICLC as an adjuvant on tuberculosis subunit vaccines. Journal of immunology. 24 (07) 568-571,2012. (in Chinese)

6. Qing Li; Juan Li, et al. IL-17 and IFN-production in peripheral blood following BCG vaccination and mycobacterium tuberculosis infection in human, European Review for Medical and Pharmacological Sciences. 16(14): 2029-2036, 2012.

7. Hongxia Niu, Lina Hu, Qing Li (corresponding author), et al. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Vaccine. 29(51): 9451-9458, 2011.

8. Qing. Li, Hongjuan. Yu; et al. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in Mice. Scandinavian Journal of Immunology. 73(6): 568-576, 2011.

9. Qing Li, Linfeng Fu, Bingxiang Wang et al. The efficacy of the fusion protein subunit vaccine boosts BCG-priming immunization in M. tuberculosis. Chinese Journal of Biological Products.23(3): 280-285，2010. (in Chinese)

10. Li Q; Guo JC; Jin HB; Cheng JS; Yang R, Involvement of taurine in
penicillin-induced epilepsy and anti-convulsion of acupuncture: a preliminary
report., Acupunct Electrother Res. 30(1-2):1-14，2005.